{"id":"W2164108760","doi":"10.1086/592052","title":"Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection","year":2008,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"Gilead Sciences; GlaxoSmithKline; Pfizer; Bristol-Myers Squibb","keywords":"Lamivudine; Zidovudine; Efavirenz; Placebo; Medicine; Reverse-transcriptase inhibitor; Internal medicine; Gastroenterology; Immunology; Viral load; Pharmacology; Human immunodeficiency virus (HIV); Viral disease; Virus; Antiretroviral therapy; Hepatitis B virus; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003432588,0.001938138,0.003337109,0.000648724,0.0005443476,0.001255153,0.001552949,0.002135396,0.004957068],"category_scores_gemma":[0.002826924,0.001131186,0.00165725,0.0004081748,0.001465577,0.001141557,0.0004324933,0.003670587,0.0009132313],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009516467,"about_ca_system_score_gemma":0.001915869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001004703,"about_ca_topic_score_gemma":0.001882524,"domain_scores_codex":[0.998385,0.001058855,0.0000742694,0.000177086,0.0001102845,0.0001945626],"domain_scores_gemma":[0.9974948,0.0008071605,0.0004239685,0.0001611997,0.000183382,0.0009295646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9388381,0.03625246,0.001162227,0.0002732634,0.0005571552,0.00004709217,0.0001163622,0.0003746419,0.007355472,0.00008722443,0.000489808,0.01444624],"study_design_scores_gemma":[0.7317952,0.2642703,0.002125143,0.00001394475,0.0001942652,0.00003531255,0.00002586798,0.0003350114,0.0006941161,0.00006354666,0.0004349531,0.00001227076],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915765,0.002329414,0.000583803,0.0003920055,0.000296289,0.003184906,0.0004729075,0.00008520282,0.00107882],"genre_scores_gemma":[0.9883876,0.001498541,0.001798885,0.0008517065,0.0004874213,0.00405611,0.0008280688,0.00002189117,0.002069726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004957068,"threshold_uncertainty_score":0.01815349,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01889415205584044,"score_gpt":0.2808378569891088,"score_spread":0.2619437049332684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}